MIT Technology Review December 22, 2025
Jessica Hamzelou

A small group of volunteers will receive multiple injections of the experimental treatments next month, says Unlimited Bio.

At some point next month, a handful of volunteers will be injected with two experimental gene therapies as part of an unusual clinical trial. The drugs are potential longevity therapies, says Ivan Morgunov, the CEO of Unlimited Bio, the company behind the trial. His long-term goal: to achieve radical human life extension.

The 12 to 15 volunteers—who will be covering their own travel and treatment costs—will receive a series of injections in the muscles of their arms and legs. One of the therapies is designed to increase the blood supply to those muscles. The other is designed to support muscle growth. The...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
What’s new with GLP-1s
Podcast: Medicaid vs. 340B: A Drug Pricing Clash (Sayeh Nikpay)
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable

Share Article